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Musculoskeletal sarcomas are rare and aggressive human malignancies affecting bones and soft tissues with severe consequences,
in terms of bothmorbidity andmortality. An innovative technique that combines photodynamic surgery (PDS) and therapy (PDT)
with acridine orange has been recently suggested, showing promising results. However, due to the low incidence of sarcoma in
humans, this procedure has been attempted only in pilot studies and stronger evidence is needed. Naturally occurring tumors in
cats are well-established and advantageous models for human cancers. Feline injection-site sarcoma (FISS) shares with human
musculoskeletal sarcomas a mesenchymal origin and an aggressive behavior with a high relapse rate. Furthermore, wide surgical
excision is not always possible due to the size and site of development. We assessed the feasibility and the effectiveness of PDS and
PDT with acridine orange to prevent FISS recurrence by treating a short case series of cats. For PDS, the surgical field was irrigated
with an acridine orange solution and exposed to UV light to enlighten the residual tumor tissue, and the resultant fluorescent
areas were trimmed. For PDT, before wound closure, the field was again irrigated with acridine orange solution and exposed to
visible light to get the antitumoral cytocidal effect. The procedure was easy to perform and well tolerated, we did not observe any
major complications, and all the surgical resection margins were free of disease. Finally, at follow-up, all treated patients did not
show evidence of tumor recurrence and had a significantly higher event-free survival rate in respect to a control group treated
only by surgery. In conclusion, by this study we demonstrated that, in FISS, PDS and PDT with acridine orange may improve
local tumor control, granting a better outcome, and we laid the foundation to validate its effectiveness for the treatment of human
musculoskeletal sarcomas.
1. Introduction
Musculoskeletal sarcomas are relatively rare human malig-
nancies that often occur in children and young adults, leading
to devastating consequences in terms of both morbidity and
mortality [1]. Currently, the gold standard therapy is surgery,
followed by chemotherapy and/or radiotherapy, but the 5-
year survival rate is still quite low [2].
Limb salvage is a well-established technique for the
treatment of musculoskeletal sarcomas and the most com-
mon approach includes wide resection followed by limb
reconstruction [3]. However, when sarcoma arises around the
forearm or the hand, involving major nerves and vessels, this
technique may cause the sacrifice of noble structures that
may lead to important limb disabilities, with a meaningful
negative impact on the quality of life.
In this context, we have recently described a novel limb
salvage technique based on the use of acridine orange for
photodynamic surgery (PDS) that is coupled with photo-
dynamic therapy (PDT) and radiodynamic therapy (RDT)
[4–8]. This innovative technique aims at improving surgery
by achieving minimally invasive excision margins and by
decreasing the number of complications for the treatment of
musculoskeletal sarcomas. Acridine orange is a fluorescent
cationic dye that is extracted from coal tar and creosote
oil. It owns metachromatic properties and various unique
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biological activities that can be harnessed in different ways:
as a fluorescent dye specific for DNA and RNA, as a pH
indicator, as a photosensitizer, as an antimalarial drug, as
a detector of bacteria and parasites, and, more importantly,
as an anticancer agent [9]. Since it has a low molecular
weight, acridine orange can easily diffuse into interstitial
tissues and cytoplasm of cells to bind cellular structures and
organelles. Due to protonation, acridine orange accumulates
into intracellular acid vesicles, leading to the formation of
membrane-impermeable monomeric, dimeric, or oligomeric
aggregates [10–12]. In this context, it is important to note that,
as first described by the Nobel Prize laureate Otto Heinrich
Warburg in 1924,malignant tumors, including musculoskele-
tal sarcomas, are highly glycolytic [13, 14]. One of the major
consequences of altered glycolytic metabolism is that tumors
aremore acidic than surrounding tissues [15]. Increased acid-
ification in cancer might also derive from oxidative cancer
cells, thus from the production of CO
2
which is hydrated into
HCO
3
− and H+ ions by carbonic anhydrases. The pentose
phosphate pathway and glutaminolysis also contribute to
CO
2
production [15]. Venting of CO
2
, H+, lactate, and/or
HCO
3
is critical to minimize cytosolic acid accumulation.
To avoid acidification of intracellular pH, acid produced by
tumor cells must be compartmentalized in acid organelles or
extruded outside the cell membrane, respectively. A various
number of protons and ions pumps and transporters, at both
the lysosome and the cytosolic membranes, are implied in
this process [16]. However, compromised blood perfusion
in tumors complicates intracellular H+ removal [15]. It is
claimed that, unlike normal cells, sarcoma cells have highly
acidic lysosomes and produce significant acidification of the
extracellular microenvironment [17–19]. Acridine orange has
thus the potential for a high and selective tropism for highly
acidifying tumor cells. When illuminated by blue light (466.5
nm) [20], or exposed to low-dose (1-5 Gy) X-ray irradiation
[21], acridine orange is cytotoxic through the generation of
singlet oxygen (1O
2
). The formed reactive species oxidize the
fatty acids of the lysosomal membrane, causing the leakage of
lysosomal enzymes and protons followed by cell death [12].
We have successfully developed and applied to clinical cases
of musculoskeletal sarcoma a combined technique of PDT
and RDT based on the use of acridine orange, demonstrating
an excellent clinical outcome in terms of inhibiting local
recurrence and preserving limb function after intra- or
marginal tumor resection [5–7, 22]. This technique proved
to be particularly advantageous in sarcomas arising around
the forearm and a valid alternative to wide surgical resection
followed by limb reconstruction, without increasing the local
recurrence rate [23].
Despite the presence of numerous pilot studies con-
cerning the use of acridine orange for the treatment of
musculoskeletal sarcomas, the low incidence of these tumors
in humans is limiting the development of clinical trials
demonstrating the efficacy of this procedure compared to
standard treatments. To extend the clinical database and
increase the statistical significance of these results, in this
studywe involved comparative oncology. Naturally occurring
tumors in animals, such as cats or dogs, are well-established
models for human cancers [24]. Their shorter lifespan is
useful for rapid trial completion and data collection, and the
lack of standard of care in most cases allows comparative
evaluation of new therapies [25].
Feline Injection Site Sarcoma (FISS) is a malignant tumor
of mesenchymal origin that develops in 1–10 of 10,000
injected cats. The pathogenesis of this disease is unknown,
although themost accepted hypothesis is a hyatrogenic origin
due to local postinjection inflammatory response that leads
to neoplastic transformation [26]. FISS has histological and
behavioral characteristics similar to human musculoskeletal
sarcomas, since it shares with these tumours a fibroblast-like
histology and an aggressive clinical behavior [26]. Indeed,
FISS has a rapid growth with a high tendency to infiltrate
the surrounding tissues, to such an extent that a wide surgical
excision is not always achievable. Furthermore, as for human
musculoskeletal sarcomas, FISS often recurs in spite of wide
surgical resection and radiotherapy, which represents the
current gold standard of therapy [27–29].
In this study, through comparative oncology, we aimed
to establish FISS as an optimum model to consolidate the
effectiveness of the combined approach PDS-PDT using
acridine orange in reducing postsurgical recurrence rate of
human musculoskeletal sarcoma.
2. Materials and Methods
2.1. Clinical Series. Starting from March 2014 and up to
April 2015, we enrolled a short case series that presented
for examination at the Veterinary Teaching Hospital of the
University of Turin (Grugliasco, Italy) with a growing mass at
injection sites. Before any procedure, the InstitutionalAnimal
Care and Use Committee approval (11 September 2011) was
obtained, and the informed consent clearly describing the
technique was signed by the animal owner, clearly describing
the technique. After a thorough physical examination, each
patient underwent a complete blood count, a biochemical
profile, and a blood test for Feline Immunodeficiency and
Feline Leukaemia Viruses (FIV, FeLV) and was diagnosed
with FISS, as confirmed by fine needle biopsy and histological
examination. The history always reported the occurrence of a
rapidly growing mass at sites of injections of vaccines or other
drugs. All cats underwent total body computed tomography
(CT) scan under general anesthesia to estimate the size of
the tumor, to determine the area of surgical excision, and to
detect lung metastases.
2.2. Procedure for Photodynamic Surgery. A standard onco-
logical resection was performed in the sternal decubitus
position, with the exception of one case for which the patient
was put in lateral decubitus due to the location of the tumor
on the lateral aspect of the thorax. The surgical excision
was performed according to the FISS treatment guidelines
[27], under general anesthesia maintained with isoflurane
(Pfizer, NY, USA) in oxygen. En-bloc resection of the tumor
was performed based on CT measurement after contrast
enhancement, with a 3 cm safety margin, removing skin,
subcutaneous tissue, andmuscle to the fascial layer below the
tumor. Hemostasis was obtained by electrosurgery (MB160,
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GIMA, Milan, Italy). Blood loss was minimal. After tumor
excision, the surgical field was first irrigated with 50 mL
sterile saline solution to remove blood clots and then with
a 50 mL of a acridine orange (1𝜇g/mL, Sigma Aldrich Co.
St. Louis, MO, USA) sterile solution and left in darkness for
10 min. After lavage with sterile saline solution, the surgical
field was excited with blue light with two different devices
that were suitable for photoactivation in the operating room:
Starlight Pro, Mectron, Genova, Italy (wavelength 488 nm),
or Rechargeable Custom Blue Light (wavelength 440/460
nm, LEM srl, Italy). The type of the device was chosen
depending on the size of the area. Fluorescent areas were
further excised with Metzenbaum scissors, until fluorescence
was no longer visible. The whole excised sample, together
with the excised residues after exposure with acridine orange,
was submitted to histopathology after inking the margins, in
order to confirm the diagnosis and evaluate the radicality of
excision.
2.3. Procedure for Photodynamicerapy. Soon after the sur-
gical procedure, the field was irrigated with a 50 mL syringe
filled with acridine orange sterile solution (1𝜇g/mL) and
exposed to surgical light (ML701, KLS Martin, Germany,
24V/250Watt, 80000 Lux) for 10 minutes, immediately after
acridine orange irrigation. Finally, the wound was sutured as
routine.
2.4. Intratumoral pH Evaluation. Immediately after the exci-
sion, the tumor pH was assessed (three replicates for each
lesion) using a portable pH Level Monitor (Hanna Instru-
ments, Padova, Italy) and recorded.
2.5. Follow-Up and Event-Free Survival Rate. After the pro-
cedure, animals were hospitalized for 2 days and reassessed
after 7 and 15 days and every 3 months thereafter for the first
year and every 6 months the second year. At each control,
starting at 3months, chest radiographs were taken to evaluate
the development of metastases and a thorough physical
examinationwas performed.After the second year the follow-
up was updated by phone call to the owners or the referring
veterinarian. As a control, we considered both a retrospective
and a prospective group of 30 FISS treated by en-bloc surgery
alone, recruited from January 2009 to September 2015. In
order to parallel the maximum follow-up time of the treated
group, the maximum follow-up considered for both groups
was 1444 days from the date of the surgery. The decision to
retrospectively recruit cases for the control group was due
to the decrease in the number of cats affected by the disease
visited in the last years, at least at the institution where the
study was conducted. Anyway, the diagnosis and staging of
each animal were accomplished in the same way, and the
surgical procedure was performed by the same surgeons in
both groups.The only variable in the procedure was the PDS-
PDT added in the study group. To evaluate the rate of success
for the PDS and PDT-treatment, the event-free survival was
calculated from the date of surgery to the date of detection of
recurrence or metastasis. The average follow-up was 902± 84
days for the control group and 961 ± 223 days for the treated
group.
2.6. Statistical Analysis. Statistical analysis was performed
by GraphPad Prism 7 software (GraphPad Software, Inc).
Quantitative results were expressed as mean ± standard error
(SEM). Due to the low number of events considered in the
study, we used nonparametric test. Survival analysis was
performed by using Kaplan-Meier survival plot (Log-rank
Mantel-Cox test). Only p < 0.05 was considered significant.
Animals were censored if they were alive and did not show
recurrence and/or metastasis at the end of the study, if they
were lost at follow-up, or if they died for reasons not related
to the tumor.
3. Results
3.1. FISS Series and PDS Treatment with Acridine Orange. In
this study we enrolled seven client-owned cats, while 30 cats
were used as control (Table 1).
The median age of the treated cats was 11 years (min 10 –
max 12); for the control group it was 11 years (min 3 – max
15). As revealed by CT scan, the maximum tumor volume,
that was calculated according to the formula: tumor volume
[cm3] = (length [cm] x width2 [cm2])/2 [30], ranged from
86.2 to 1362.4 mm3 (median 193.6 cm3) for the treated group
and 0.25 to 1316 cm3 (median 132 cm3) for the control group.
Representative CT scans for the treated group are shown in
Figure 1 and histology is shown in Figure 2.
After tumor resection, themedian pH valuewas 6.14 (min
6.08, max 6.84, Table 2).
PDS and PDT are summarized in Figure 3.
Resection of spinous processes of adjacent vertebrae was
needed in three cases (#2, 3, and 7). Overall, the surgery
time was 30 minutes longer as compared to the standard
surgical procedure. No major complications were observed.
The procedure was well tolerated by the animals. Tumor-free
excision margins were obtained in all cases.
3.2. Impact of PDS and PDT on FISS Recurrence Rate. Two
patients (#3, 6) were euthanized for unrelated causes after
60 and 173 days from surgery (infectious viral peritonitis
and chronic bowel disease, respectively), and they did not
present evidence of local or systemic relapse of the tumor
at the time of death. All remaining cats were alive and did
not develop recurrence and/or metastasis at the time of last
follow-up.TheKaplan-Meier analysis was applied to estimate
the survival rate. Although no significant association was
found with local recurrence rate (data not shown), the PDS
and PDT treatment was associated with a significantly higher
event-free survival rate in comparison with the control group
(Figure 4, p = 0.0482). 12 out of 30 cases developed local
recurrence (40%), and 17 out of 30 developed local recurrence
and/or lung metastasis (56.6%).
4. Discussion
Intratumoral acidosis is a hallmark of cancer [14–16], and
sinceOttoWarburg’s reports in 1925, evidence of a correlation
between tumor glycolysis and extracellular acidosis has been
demonstrated by several techniques, including acidoCEST
MRI and [18F]FDG PET [31, 32], suggesting an inverse
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Figure 1: Preoperative CT scan of cats # 2 and 3 of the treated group. The extent of the tumor after contrast medium administration was
considered including the lateral laciniae; infiltration into surrounding tissues and the vicinity with spinal processes were assessed.
Table 2: Intratumoral pH.
Case Tumour size pH
# width x length [cm]
1 5.0x8.8 n.d.
2 8.5x9.0 6.14
3 9.0x17.4 6.26
4 5.5x5.6 6.08
5 7.3x10.7 6.10
6 6.0x7.0 6.84
7 10.0x5.0 n.d.
n.d., not determined.
correlation between extracellular tumor pH and [18F]FDG
uptake. Other factors, besides increased glycolysis, have been
suggested as responsible for the induction of intratumoral
acidosis, such as the production of CO
2
duringmitochondrial
respiration when combined with a defective proton-venting
cellular mechanism [15]. Intratumoral acidosis may be used
as a selective anticancer target, and different antiacid thera-
peuticmodalities have been developed, such as neutralization
of tumor-derived acid by systemic buffers, proton pump
inhibitors, or carbonic anhydrase inhibitors [15, 18, 33, 34].
The use of pH-sensitive drug-delivery nanocarriers has also
been proposed [15, 35]. Photodynamic technology may be
exploited as an additional anticancer approach for acid
microenvironment. Photoactivation involves activating or
inactivating specific molecules using light. Light causes the
activation, inhibition, or conformational changes in these
molecules. As an example, drug photoactivation has been
tested for the treatment of cancer, as demonstrated in several
types of carcinomas and in glioblastoma [36–40]. In this
study, we used PDS and PDT based on acridine orange, a
fluorescent cationic dye with notably advantageous features,
since it selectively targets acidifying tissue [41], is not tumori-
genic in humans, mice, rats, or rabbits [42], and has been
suggested for clinical application [4]. Regarding PDS, acri-
dine orange is an innovative tool to increase surgery efficacy,
since it avoids the need for wide surgical margins, thereby
reducing postsurgery disabilities [43]. Acridine orange gives
a further advantage by exploiting of the PDT action since
its cytotoxicity is selective against cancer cells. Indeed, this
molecule accumulates into lysosomes that are highly acidic,
and, when photoactivated, it causes lysosomal membrane
permeabilization, by the formation of oxygen single species
[12], and the consequent leakage of the lysosomal content
into the cytosol, leading to the so-called “lysosomal cell
death.” This form of cell death can have necrotic, apoptotic,
or apoptosis-like features depending on the extent of the
leakage and the cellular context [44]. Malignant transfor-
mation is associated with alterations in lysosomal structure
and function, which, paradoxically, render cancer cells more
sensitive to lysosomal destabilization [45]. Similarly to other
types of cancers, sarcoma cells have very acidic lysosomes,
especially in the case of cancer stem cells and drug-resistant
cells [33, 46].
Despite the preclinical evidence of the potential of acri-
dine orange combined to PDS and PDT to treat sarcomas,
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Figure 2: Histopathological image of FISS (Courtesy of dr. S.
Iussich). Upper panel, multiple nodules of fusiform cells arranged
in sheets in abundant hyaline stroma infiltrating the subcutaneous
tissue (H&E, 2x objective); lower panel,multiple nodules of fusiform
cells arranged in sheets in moderate myxoid stroma; the cells (20-
30 𝜇 in diameter) are characterized by scant cytoplasm, ovalar and
vesicular nuclei with 1 nucleolus not always visible; lowmitotic index
(0-1/HPF) (H&E, 20x objective).
the low incidence of these malignancies in humans has not
allowed a wide application of such technique. In this context,
comparative oncology may greatly help in the evaluation and
interpretation of the response to treatment, especially when
human and animal diseases are biologically and clinically
similar [47], as in the case of sarcomas.
In this pilot study, we enrolled cats with FISS, a soft
tissue sarcoma with clinical futures very similar to those of
human tumors, including an aggressive local behavior. Up
to one-quarter of cats with this condition have metastatic
lung involvement, but the major concern is related to the
high recurrence rate of the disease.Themainstay of treatment
is aggressive surgery, but even in cases of wide excision
with clean margins, tumor recurrence occurs in a high
proportion of cases [48–51]. The effectiveness of adjunctive
chemotherapy is still controversial [29], and radiotherapy
is still not widely available in veterinary medicine. In such
contest, PDS and PDT may be of great advantage, allowing a
thorough excision, thereby reducing the extent of the excision
area and postoperative morbidity. PDT has already been
studied in FISS, based on the use of indocyanine green com-
bined to hyperthermal chemotherapy following conservative
surgical resection [52]. In our series, cats were treated with
acridine orange-based PDS and PDT, a treatment already
tested in different pilot studies on malignant musculoskeletal
tumors in humans [8, 41, 53–55]. Tumor samples showed
a low intratumoral pH. As the blood loss during surgery
was minimal, the pH measurement was not affected by the
buffering activitymediated by bicarbonate in the blood.These
data demonstrate that FISS is an acid-producing tumor to
an extent similar to those of the most aggressive human
sarcomas. In fact, Matsubara et al. have previously reported
that intratumoral pH of malignant musculoskeletal tumors is
6.78 ± 0.26 [41], and Engin et al. reported an intratumoral
pH value for soft tissue sarcomas of 7.01 ± 0.21[56]. Notably,
normal tissues, such as muscle or adipose tissue, have an
interstitial pH of 7.26 ± 0.14 and 7.43 ± 0.11, respectively [41].
After the execution of PDS and PDT, we did not observe
any adverse event, neither during nor in the immediate
follow-up. The procedure was very similar to that previously
used in human patients with sarcomas [4, 54], with the
only exception that we used surgical loupes in place of a
surgical microscope. For the local recurrence rate, although
we did observe a trend of reduction after the PDS and PDT
treatment, this difference was not significant in respect to
the control group, possibly because of the low number of
cases enrolled in the study.However, we obtained a significant
reduction of tumor relapse, intended as local recurrence or
development of lung metastasis, thereby suggesting that the
local control might have a positive effect in preventing the
formation of metastasis at distant sites. These unexpected
results might reflect the occurrence of a bystander effect
(abscopal effect) that has been observed after radiation
therapy in several types of cancer, including sarcoma [57].
In radioimmunobiologic terms, abscopal effects describe the
radiotherapy-induced regression of cancerous lesions distant
from the primary site of radiation delivery and rely upon the
induction of immunogenic cell death and consequent sys-
temic anticancer immune activation. Similarly, the treatment
with PDT might have induced the necrosis of the remaining
infiltrated tumor cells after the PDS treatment, close to the
tumor resection site, thereby causing the release of tumor-
associated antigens that, in turn, might have sensitized and
enhanced the host immune surveillance against the systemic
residual disease.
The recurrence rate observed in the control group was
higher compared to what is reported by the most recent
veterinary literature [28]; this was because some of the cats
presented with very large tumors that would have greatly
benefited from adjuvant radiotherapy, which was declined by
the owners. In these cases, wide surgical margins were not
achievable, and this may explain the outcome.
5. Conclusions
Our data suggest that PDS-PDT based on the use of acridine
orange has the potential to exert a similar effect in compari-
son to the gold standard treatment of FISS and that, according
to the results obtained by analyzing a pilot series of animal
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Figure 3: Graphical representation of acridine orange PDS and PDT technique. Surgical excision (a), pH measurement (b), acridine orange
irrigation (c), PDS (d), PDT (e). On the bottom line, representative photographs of the procedure are shown.
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Figure 4: Effect of PDS and PDT with acridine orange on FISS
disease-free survival time at follow-up, as analyzed byKaplan-Meier.
Both local recurrence and metastasis are considered as event (n. of
uncensored events was 17 for control and 0 for treated, out of 30 and
7 patients, respectively).
patients with FISS, this technique may be considered a useful
adjuvant therapeutic modality.
Our data lay the foundation for additional research
in this spontaneous animal condition that may foster the
development of novel treatment options to be translated for
human musculoskeletal sarcomas.
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